Portraits of TET-mediated DNA hydroxymethylation in cancer

Current Opinion in Genetics and Development

Volumn 36, Issue , 2016, Pages 16-26

  Jeschke, Jana ^a   Collignon, Evelyne ^a   Fuks, François ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLCYTOSINE; ASCORBIC ACID; TEN ELEVEN TRANSLOCATION PROTEIN; UNCLASSIFIED DRUG; 5 METHYLCYTOSINE; DNA BINDING PROTEIN; MIXED FUNCTION OXIDASE; ONCOPROTEIN; TET1 PROTEIN, HUMAN;

BIOLOGICAL FUNCTIONS; CANCER GENETICS; CANCER IMMUNOLOGY; CANCER INHIBITION; DNA METHYLATION; ENZYME SUBSTRATE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; MOLECULAR BIOLOGY; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONTENT; PROTEIN DEFECT; PROTEIN DNA INTERACTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; REVIEW; SOLID TUMOR; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NEOPLASM;

5-METHYLCYTOSINE; DNA METHYLATION; DNA-BINDING PROTEINS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HUMANS; MIXED FUNCTION OXYGENASES; NEOPLASMS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS;

EID: 84957802353     PISSN: 0959437X     EISSN: 18790380     Source Type: Journal    
DOI: 10.1016/j.gde.2016.01.004     Document Type: Review

References (105)

1. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734.
2. Sandoval J., Esteller M. Cancer epigenomics: beyond genomics. Curr Opin Genet Dev 2012, 22:50-55.
3. Ono R., Taki T., Taketani T., Taniwaki M., Kobayashi H., Hayashi Y. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23). Cancer Res 2002, 62:4075-4080.
4. Lorsbach R.B., Moore J., Mathew S., Raimondi S.C., Mukatira S.T., Downing J.R. TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 2003, 17:637-641.
5. Tahiliani M., Koh K.P., Shen Y., Pastor W.A., Bandukwala H., Brudno Y., Agarwal S., Iyer L.M., Liu D.R., Aravind L., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
6. He Y.F., Li B.Z., Li Z., Liu P., Wang Y., Tang Q., Ding J., Jia Y., Chen Z., Li L., et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333:1303-1307.
7. Ito S., Shen L., Dai Q., Wu S.C., Collins L.B., Swenberg J.A., He C., Zhang Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333:1300-1303.
8. Valinluck V., Sowers L.C. Endogenous cytosine damage products alter the site selectivity of human DNA maintenance methyltransferase DNMT1. Cancer Res 2007, 67:946-950.
9. Hashimoto H., Liu Y., Upadhyay A.K., Chang Y., Howerton S.B., Vertino P.M., Zhang X., Cheng X. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res 2012, 40:4841-4849.
10. Maiti A., Drohat A.C. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem 2011, 286:35334-35338.
11. Zhang L., Lu X., Lu J., Liang H., Dai Q., Xu G.L., Luo C., Jiang H., He C. Thymine DNA glycosylase specifically recognizes 5-carboxylcytosine-modified DNA. Nat Chem Biol 2012, 8:328-330.
12. Guo J.U., Su Y., Zhong C., Ming G.L., Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011, 145:423-434.
13. Huang Y., Chavez L., Chang X., Wang X., Pastor W.A., Kang J., Zepeda-Martinez J.A., Pape U.J., Jacobsen S.E., Peters B., et al. Distinct roles of the methylcytosine oxidases Tet1 and Tet2 in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2014, 111:1361-1366.
14. Bachman M., Uribe-Lewis S., Yang X., Williams M., Murrell A., Balasubramanian S. 5-Hydroxymethylcytosine is a predominantly stable DNA modification. Nat Chem 2014, 6:1049-1055.
15. Mellen M., Ayata P., Dewell S., Kriaucionis S., Heintz N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 2012, 151:1417-1430.
16. Spruijt C.G., Gnerlich F., Smits A.H., Pfaffeneder T., Jansen P.W., Bauer C., Munzel M., Wagner M., Muller M., Khan F., et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152:1146-1159.
17. Zhang H., Zhang X., Clark E., Mulcahey M., Huang S., Shi Y.G. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res 2010, 20:1390-1393.
18. Xu Y., Wu F., Tan L., Kong L., Xiong L., Deng J., Barbera A.J., Zheng L., Zhang H., Huang S., et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011, 42:451-464.
19. Xu Y., Xu C., Kato A., Tempel W., Abreu J.G., Bian C., Hu Y., Hu D., Zhao B., Cerovina T., et al. Tet3 CXXC domain and dioxygenase activity cooperatively regulate key genes for Xenopus eye and neural development. Cell 2012, 151:1200-1213.
20. Ko M., An J., Bandukwala H.S., Chavez L., Aijo T., Pastor W.A., Segal M.F., Li H., Koh K.P., Lahdesmaki H., et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature 2013, 497:122-126.
21. Ito S., D'Alessio A.C., Taranova O.V., Hong K., Sowers L.C., Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010, 466:1129-1133.
22. Ficz G., Branco M.R., Seisenberger S., Santos F., Krueger F., Hore T.A., Marques C.J., Andrews S., Reik W. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011, 473:398-402.
23. Szulwach K.E., Li X., Li Y., Song C.X., Wu H., Dai Q., Irier H., Upadhyay A.K., Gearing M., Levey A.I., et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci 2011, 14:1607-1616.
24. Stroud H., Feng S., Morey Kinney S., Pradhan S., Jacobsen S.E. 5-Hydroxymethylcytosine is associated with enhancers and gene bodies in human embryonic stem cells. Genome Biol 2011, 12:R54.
25. Madzo J., Liu H., Rodriguez A., Vasanthakumar A., Sundaravel S., Caces D.B., Looney T.J., Zhang L., Lepore J.B., Macrae T., et al. Hydroxymethylation at gene regulatory regions directs stem/early progenitor cell commitment during erythropoiesis. Cell Rep 2014, 6:231-244.
26. Koh K.P., Yabuuchi A., Rao S., Huang Y., Cunniff K., Nardone J., Laiho A., Tahiliani M., Sommer C.A., Mostoslavsky G., et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011, 8:200-213.
27. Gu T.P., Guo F., Yang H., Wu H.P., Xu G.F., Liu W., Xie Z.G., Shi L., He X., Jin S.G., et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011, 477:606-610.
28. Moran-Crusio K., Reavie L., Shih A., Abdel-Wahab O., Ndiaye-Lobry D., Lobry C., Figueroa M.E., Vasanthakumar A., Patel J., Zhao X., et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011, 20:11-24.
29. Ko M., Bandukwala H.S., An J., Lamperti E.D., Thompson E.C., Hastie R., Tsangaratou A., Rajewsky K., Koralov S.B., Rao A. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 2011, 108:14566-14571.
30. Li Z., Cai X., Cai C.L., Wang J., Zhang W., Petersen B.E., Yang F.C., Xu M. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011, 118:4509-4518.
31. Quivoron C., Couronne L., Della Valle V., Lopez C.K., Plo I., Wagner-Ballon O., Do Cruzeiro M., Delhommeau F., Arnulf B., Stern M.H., et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011, 20:25-38.
32. Dawson M.A., Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150:12-27.
33. Huang Y., Rao A. Connections between TET proteins and aberrant DNA modification in cancer. Trends Genet 2014, 30:464-474.
34. Ko M., An J., Pastor W.A., Koralov S.B., Rajewsky K., Rao A. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol Rev 2015, 263:6-21.
35. Coutinho D.F., Monte-Mor B.C., Vianna D.T., Rouxinol S.T., Batalha A.B., Bueno A.P., Boulhosa A.M., Fernandez T.S., Pombo-de-Oliveira M.S., Gutiyama L.M., et al. TET2 expression level and 5-hydroxymethylcytosine are decreased in refractory cytopenia of childhood. Leuk Res 2015, 39:1103-1108.
36. Haffner M.C., Chaux A., Meeker A.K., Esopi D.M., Gerber J., Pellakuru L.G., Toubaji A., Argani P., Iacobuzio-Donahue C., Nelson W.G., et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011, 2:627-637.
37. Lian C.G., Xu Y., Ceol C., Wu F., Larson A., Dresser K., Xu W., Tan L., Hu Y., Zhan Q., et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 2012, 150:1135-1146.
38. Murata A., Baba Y., Ishimoto T., Miyake K., Kosumi K., Harada K., Kurashige J., Iwagami S., Sakamoto Y., Miyamoto Y., et al. TET family proteins and 5-hydroxymethylcytosine in esophageal squamous cell carcinoma. Oncotarget 2015, 6:23372-23382.
39. Udali S., Guarini P., Moruzzi S., Ruzzenente A., Tammen S.A., Guglielmi A., Conci S., Pattini P., Olivieri O., Corrocher R., et al. Global DNA methylation and hydroxymethylation differ in hepatocellular carcinoma and cholangiocarcinoma and relate to survival rate. Hepatology 2015, 62:496-504.
40. Huang H., Jiang X., Li Z., Li Y., Song C.X., He C., Sun M., Chen P., Gurbuxani S., Wang J., et al. TET1 plays an essential oncogenic role in MLL-rearranged leukemia. Proc Natl Acad Sci U S A 2013, 110:11994-11999.
41. Navarro A., Yin P., Ono M., Monsivais D., Moravek M.B., Coon JSt, Dyson M.T., Wei J.J., Bulun S.E. 5-Hydroxymethylcytosine promotes proliferation of human uterine leiomyoma: a biological link to a new epigenetic modification in benign tumors. J Clin Endocrinol Metab 2014, 99:E2437-E2445.
42. Thomson J.P., Nestor C.E., Meehan R.R. 5-Hydroxymethylcytosine profiling in human DNA. Methods Mol Biol 2015.
43. Bhattacharyya S., Yu Y., Suzuki M., Campbell N., Mazdo J., Vasanthakumar A., Bhagat T.D., Nischal S., Christopeit M., Parekh S., et al. Genome-wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer. Nucleic Acids Res 2013, 41:e157.
44. Thomson J.P., Hunter J.M., Lempiainen H., Muller A., Terranova R., Moggs J.G., Meehan R.R. Dynamic changes in 5-hydroxymethylation signatures underpin early and late events in drug exposed liver. Nucleic Acids Res 2013, 41:5639-5654.
45. Uribe-Lewis S., Stark R., Carroll T., Dunning M.J., Bachman M., Ito Y., Stojic L., Halim S., Vowler S.L., Lynch A.G., et al. 5-Hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer. Genome Biol 2015, 16:69.
46. Rampal R., Alkalin A., Madzo J., Vasanthakumar A., Pronier E., Patel J., Li Y., Ahn J., Abdel-Wahab O., Shih A., et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep 2014, 9:1841-1855.
47. Rasmussen K.D., Jia G., Johansen J.V., Pedersen M.T., Rapin N., Bagger F.O., Porse B.T., Bernard O.A., Christensen J., Helin K. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev 2015, 29:910-922.
48. Nestor C.E., Ottaviano R., Reddington J., Sproul D., Reinhardt D., Dunican D., Katz E., Dixon J.M., Harrison D.J., Meehan R.R. Tissue type is a major modifier of the 5-hydroxymethylcytosine content of human genes. Genome Res 2012, 22:467-477.
49. Hu L., Li Z., Cheng J., Rao Q., Gong W., Liu M., Shi Y.G., Zhu J., Wang P., Xu Y. Crystal structure of TET2-DNA complex: insight into TET-mediated 5mC oxidation. Cell 2013, 155:1545-1555.
50. Tefferi A. Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up?. Leukemia 2011, 25:1059-1063.
51. Shih A.H., Abdel-Wahab O., Patel J.P., Levine R.L. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012, 12:599-612.
52. Ortmann C.A., Kent D.G., Nangalia J., Silber Y., Wedge D.C., Grinfeld J., Baxter E.J., Massie C.E., Papaemmanuil E., Menon S., et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 2015, 372:601-612.
53. Abdel-Wahab O., Mullally A., Hedvat C., Garcia-Manero G., Patel J., Wadleigh M., Malinge S., Yao J., Kilpivaara O., Bhat R., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114:144-147.
54. Dolnik A., Engelmann J.C., Scharfenberger-Schmeer M., Mauch J., Kelkenberg-Schade S., Haldemann B., Fries T., Kronke J., Kuhn M.W., Paschka P., et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 2012, 120:e83-e92.
55. Palomero T., Couronne L., Khiabanian H., Kim M.Y., Ambesi-Impiombato A., Perez-Garcia A., Carpenter Z., Abate F., Allegretta M., Haydu J.E., et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014, 46:166-170.
56. Seshagiri S., Stawiski E.W., Durinck S., Modrusan Z., Storm E.E., Conboy C.B., Chaudhuri S., Guan Y., Janakiraman V., Jaiswal B.S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488:660-664.
57. Sato Y., Yoshizato T., Shiraishi Y., Maekawa S., Okuno Y., Kamura T., Shimamura T., Sato-Otsubo A., Nagae G., Suzuki H., et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013, 45:860-867.
58. Nickerson M.L., Im K.M., Misner K.J., Tan W., Lou H., Gold B., Wells D.W., Bravo H.C., Fredrikson K.M., Harkins T.T., et al. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat 2013, 34:1231-1241.
59. Wang Y., Thomas A., Lau C., Rajan A., Zhu Y., Killian J.K., Petrini I., Pham T., Morrow B., Zhong X., et al. Mutations of epigenetic regulatory genes are common in thymic carcinomas. Sci Rep 2014, 4:7336.
60. Sun M., Song C.X., Huang H., Frankenberger C.A., Sankarasharma D., Gomes S., Chen P., Chen J., Chada K.K., He C., et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A 2013, 110:9920-9925.
61. Song S.J., Poliseno L., Song M.S., Ala U., Webster K., Ng C., Beringer G., Brikbak N.J., Yuan X., Cantley L.C., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 2013, 154:311-324.
62. Cheng J., Guo S., Chen S., Mastriano S.J., Liu C., D'Alessio A.C., Hysolli E., Guo Y., Yao H., Megyola C.M., et al. An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep 2013, 5:471-481.
63. Chuang K.H., Whitney-Miller C.L., Chu C.Y., Zhou Z., Dokus M.K., Schmit S., Barry C.T. MicroRNA-494 is a master epigenetic regulator of multiple invasion-suppressor microRNAs by targeting ten eleven translocation 1 in invasive human hepatocellular carcinoma tumors. Hepatology 2015, 62:466-480.
64. Chim C.S., Wan T.S., Fung T.K., Wong K.F. Methylation of TET2, CBL and CEBPA in Ph-negative myeloproliferative neoplasms. J Clin Pathol 2010, 63:942-946.
65. Kim Y.H., Pierscianek D., Mittelbronn M., Vital A., Mariani L., Hasselblatt M., Ohgaki H. TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations. J Clin Pathol 2011, 64:850-852.
66. Cimmino L., Dawlaty M.M., Ndiaye-Lobry D., Yap Y.S., Bakogianni S., Yu Y., Bhattacharyya S., Shaknovich R., Geng H., Lobry C., et al. TET1 is a tumor suppressor of hematopoietic malignancy. Nat Immunol 2015, 16:653-662.
67. Wang Y., Zhang Y. Regulation of TET protein stability by calpains. Cell Rep 2014, 6:278-284.
68. Storr S.J., Carragher N.O., Frame M.C., Parr T., Martin S.G. The calpain system and cancer. Nat Rev Cancer 2011, 11:364-374.
69. Ciccarone F., Valentini E., Zampieri M., Caiafa P. 5mC-hydroxylase activity is influenced by the PARylation of TET1 enzyme. Oncotarget 2015, 6:24333-24347.
70. Nakagawa T., Lv L., Nakagawa M., Yu Y., Yu C., D'Alessio A.C., Nakayama K., Fan H.Y., Chen X., Xiong Y. CRL4(VprBP) E3 ligase promotes monoubiquitylation and chromatin binding of TET dioxygenases. Mol Cell 2015, 57:247-260.
71. Dang L., Jin S., Su S.M. IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med 2010, 16:387-397.
72. Losman J.A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., Cowley G.S., Root D.E., Ebert B.L., Kaelin W.G. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625.
73. Ye D., Ma S., Xiong Y., Guan K.L. R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis. Cancer Cell 2013, 23:274-276.
74. Xiao M., Yang H., Xu W., Ma S., Lin H., Zhu H., Liu L., Liu Y., Yang C., Xu Y., et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 2012, 26:1326-1338.
75. Adam J., Yang M., Soga T., Pollard P.J. Rare insights into cancer biology. Oncogene 2014, 33:2547-2556.
76. Killian J.K., Miettinen M., Walker R.L., Wang Y., Zhu Y.J., Waterfall J.J., Noyes N., Retnakumar P., Yang Z., Smith W.I., et al. Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 2014, 6:268ra177.
77. Shi F.T., Kim H., Lu W., He Q., Liu D., Goodell M.A., Wan M., Songyang Z. Ten-eleven translocation 1 (Tet1) is regulated by O-linked N-acetylglucosamine transferase (Ogt) for target gene repression in mouse embryonic stem cells. J Biol Chem 2013, 288:20776-20784.
78. Zhang Q., Liu X., Gao W., Li P., Hou J., Li J., Wong J. Differential regulation of the ten-eleven translocation (TET) family of dioxygenases by O-linked beta-N-acetylglucosamine transferase (OGT). J Biol Chem 2014, 289:5986-5996.
79. Du J., Cullen J.J., Buettner G.R. Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 2012, 1826:443-457.
80. Yin R., Mao S.Q., Zhao B., Chong Z., Yang Y., Zhao C., Zhang D., Huang H., Gao J., Li Z., et al. Ascorbic acid enhances Tet-mediated 5-methylcytosine oxidation and promotes DNA demethylation in mammals. J Am Chem Soc 2013, 135:10396-10403.
81. Minor E.A., Court B.L., Young J.I., Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem 2013, 288:13669-13674.
82. Blaschke K., Ebata K.T., Karimi M.M., Zepeda-Martinez J.A., Goyal P., Mahapatra S., Tam A., Laird D.J., Hirst M., Rao A., et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 2013, 500:222-226.
83. Gustafson C.B., Yang C., Dickson K.M., Shao H., Van Booven D., Harbour J.W., Liu Z.J., Wang G. Epigenetic reprogramming of melanoma cells by vitamin C treatment. Clin Epigenetics 2015, 7:51.
84. Delhommeau F., Dupont S., Della Valle V., James C., Trannoy S., Masse A., Kosmider O., Le Couedic J.P., Robert F., Alberdi A., et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 360:2289-2301.
85. Ko M., Huang Y., Jankowska A.M., Pape U.J., Tahiliani M., Bandukwala H.S., An J., Lamperti E.D., Koh K.P., Ganetzky R., et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010, 468:839-843.
86. Yamazaki J., Taby R., Vasanthakumar A., Macrae T., Ostler K.R., Shen L., Kantarjian H.M., Estecio M.R., Jelinek J., Godley L.A., et al. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 2012, 7:201-207.
87. Abdel-Wahab O., Gao J., Adli M., Dey A., Trimarchi T., Chung Y.R., Kuscu C., Hricik T., Ndiaye-Lobry D., Lafave L.M., et al. Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 2013, 210:2641-2659.
88. Muto T., Sashida G., Oshima M., Wendt G.R., Mochizuki-Kashio M., Nagata Y., Sanada M., Miyagi S., Saraya A., Kamio A., et al. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 2013, 210:2627-2639.
89. Lobry C., Ntziachristos P., Ndiaye-Lobry D., Oh P., Cimmino L., Zhu N., Araldi E., Hu W., Freund J., Abdel-Wahab O., et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013, 210:301-319.
90. Shih A.H., Jiang Y., Meydan C., Shank K., Pandey S., Barreyro L., Antony-Debre I., Viale A., Socci N., Sun Y., et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell 2015, 27:502-515.
91. Hsu C.H., Peng K.L., Kang M.L., Chen Y.R., Yang Y.C., Tsai C.H., Chu C.S., Jeng Y.M., Chen Y.T., Lin F.M., et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell Rep 2012, 2:568-579.
92. Yang H., Liu Y., Bai F., Zhang J.Y., Ma S.H., Liu J., Xu Z.D., Zhu H.G., Ling Z.Q., Ye D., et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013, 32:663-669.
93. Wu B.K., Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep 2014, 9:1827-1840.
94. Neri F., Dettori D., Incarnato D., Krepelova A., Rapelli S., Maldotti M., Parlato C., Paliogiannis P., Oliviero S. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway. Oncogene 2015, 34:4168-4176.
95. Ahsan S., Raabe E.H., Haffner M.C., Vaghasia A., Warren K.E., Quezado M., Ballester L.Y., Nazarian J., Eberhart C.G., Rodriguez F.J. Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma. Acta Neuropathol Commun 2014, 2:59.
96. Mariani C.J., Vasanthakumar A., Madzo J., Yesilkanal A., Bhagat T., Yu Y., Bhattacharyya S., Wenger R.H., Cohn S.L., Nanduri J., et al. TET1-mediated hydroxymethylation facilitates hypoxic gene induction in neuroblastoma. Cell Rep 2014, 7:1343-1352.
97. Tsai Y.P., Chen H.F., Chen S.Y., Cheng W.C., Wang H.W., Shen Z.J., Song C., Teng S.C., He C., Wu K.J. TET1 regulates hypoxia-induced epithelial-mesenchymal transition by acting as a co-activator. Genome Biol 2014, 15:513.
98. Lund K., Adams P.D., Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia 2014, 28:44-49.
99. Jeschke J., Collignon E., Fuks F. DNA methylome profiling beyond promoters - taking an epigenetic snapshot of the breast tumor microenvironment. FEBS J 2015, 282:1801-1814.
100. Yang R., Qu C., Zhou Y., Konkel J.E., Shi S., Liu Y., Chen C., Liu S., Liu D., Chen Y., et al. Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity 2015, 43:251-263.
101. Zhang Q., Zhao K., Shen Q., Han Y., Gu Y., Li X., Zhao D., Liu Y., Wang C., Zhang X., et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015, 525:389-393.
102. Ichiyama K., Chen T., Wang X., Yan X., Kim B.S., Tanaka S., Ndiaye-Lobry D., Deng Y., Zou Y., Zheng P., et al. The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 2015, 42:613-626.
103. Perez C., Martinez-Calle N., Martin-Subero J.I., Segura V., Delabesse E., Fernandez-Mercado M., Garate L., Alvarez S., Rifon J., Varea S., et al. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia. PLoS One 2012, 7:e31605.
104. Yamazaki J., Jelinek J., Lu Y., Cesaroni M., Madzo J., Neumann F., He R., Taby R., Vasanthakumar A., Macrae T., et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor-binding sites in chronic myelomonocytic leukemia. Cancer Res 2015, 75:2833-2843.
105. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., Li Y., Bhagwat N., Vasanthakumar A., Fernandez H.F., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010, 18:553-567.